Cannapharmarx Inc (CPMD)
OTHER OTC:CPMD
US Market
Holding CPMD?
Track your performance easily

Cannapharmarx (CPMD) Income Statement

56 Followers

Cannapharmarx Income Statement

Last quarter (Q2 2024), Cannapharmarx's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Cannapharmarx's net income was $5.36M. See Cannapharmarx’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 25.84K-----
Cost of Revenue
$ 463.25K-----
Gross Profit
$ -437.41K-----
Operating Expense
$ 560.52K$ 1.48M$ 5.10M$ 2.62M$ 4.64M$ 2.98M
Operating Income
$ -997.93K$ -1.48M$ -5.10M$ -2.62M$ -4.64M$ -2.98M
Net Non Operating Interest Income Expense
$ -2.19M$ -1.70M$ -2.29M$ 1.51M$ 2.29M$ 4.47M
Other Income Expense
$ -4.45M$ -7.04M$ 1.03M$ -4.71M$ -12.96M$ -13.00M
Pretax Income
$ 727.27K$ 3.79M$ -8.43M$ -8.83M$ -19.89M$ -20.45M
Tax Provision
$ 100.03K$ 100.03K$ 103.61K---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 627.24K$ 3.69M$ -8.53M$ -8.83M$ -19.89M$ -20.45M
Basic EPS
$ <0.01$ 0.01$ -0.04$ -0.12$ -0.49$ -0.66
Diluted EPS
$ <0.01$ 0.01$ -0.04$ -0.12$ -0.49$ -0.66
Basic Average Shares
$ 1.65B$ 308.94M$ 211.04M$ 74.69M$ 40.70M$ 31.17M
Diluted Average Shares
$ 1.65B$ 308.94M$ 211.04M$ 74.69M$ 40.70M$ 31.17M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 1.02M$ 1.48M$ 5.10M$ -2.62M$ -4.64M$ -2.98M
Net Income From Continuing And Discontinued Operation
$ 627.24K$ 3.69M$ -8.53M$ -8.83M$ -19.89M$ -20.45M
Normalized Income
$ -1.23M$ 2.86M$ -6.19M$ -5.29M$ -5.34M$ -2.03M
Interest Expense
------
EBIT
$ 2.92M$ 5.49M$ -6.13M$ -7.33M$ -17.60M$ -15.98M
EBITDA
$ 2.96M$ 5.61M$ -5.36M$ -7.32M$ -17.47M$ -15.85M
Currency in USD

Cannapharmarx Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis